Acurx Pharmaceuticals, Inc. (ACXP)

NCM – Real Time Price. Currency in USD

1.52

+0.10 (7.04%)

At close: Jun 26, 2026, 4:00 PM EDT

1.48

-0.04 (-2.63%)

After-hours: Jun 26, 2026, 7:55 PM EDT

16.06.2026

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis of inhalation anthrax being planned in parallel Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y., June 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections.

08.06.2026

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

12.05.2026

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

12.05.2026

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2026.

04.05.2026

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx DNA pol IIIC inhibitors, linezolid, or placebo administered orally Acurx compounds achieved potentially therapeutic plasma levels and reduced MRSA tissue burden Acurx antibiotics maintained a substantially higher gut microbial diversity and a community structure similar to baseline and distinct from linezolid Unlike linezolid, ACX compounds maintain Bacteroidota-dominant community structure and prevent Proteobacteria expansion in the gastrointestinal tract DNA pol IIIC inhibitors demonstrate a class effect of potentially clinically-relevant gut microbiome preservation while demonstrating systemic antibacterial activity Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC STATEN ISLAND, N.Y., May 4, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced presentation of a scientific poster at the 35th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) held in Munich, Germany from April 17-21, 2026.

29.04.2026

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections announced today that David P.

27.04.2026

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 05:20 PM ET at the historic Bank of New York.

Videos

No Data

There is no data to display

Press releases

16.06.2026

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

12.05.2026

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

04.05.2026

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

16.04.2026

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules.

Acurx Pharmaceuticals, Inc. (ACXP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Search stocks

Acurx Pharmaceuticals, Inc. (ACXP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Videos

No Data

Press releases

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules